Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MCL-1 inhibitors – where are we now (2019)?

1 Oct 2019

Abstract excerpt

Introduction: Myeloid cell leukemia-1 (MCL-1) is an anti-apoptotic member of the B-cell lymphoma-2 (BCL-2) family of proteins that regulates apoptosis. Elevated levels of MCL-1 contribute to tumorigenesis and resistance, not only to conventional chemotherapies but also to targeted therapies, including the BCL-2 selective inhibitor venetoclax. Accordingly, researchers in both the pharmaceutical industry and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Nanoparticle-Based Drug Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31566022
DOI: 10.1080/13543776.2019.1672661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MCL-1 inhibitors – where are we now (2019)?PMID 31566022Read ↗

Mcl-1 inhibitors: a patent reviewSemantic proximity Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSemantic proximity Read ↗

Mcl‐1 targeting could be an intriguing perspective to cure cancerSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell MalignanciesSemantic proximity Read ↗

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.Semantic proximity Read ↗

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancerSemantic proximity Read ↗

Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)Semantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.